Galectin Therapeutics (GALT) Current Deferred Revenue (2010 - 2012)

Galectin Therapeutics' Current Deferred Revenue history runs 3 years deep, the most recent figure standing at $200000.0 for Q2 2012.

• In Q2 2012, Current Deferred Revenue changed 0.0% year-over-year to $200000.0; the TTM figure through Jun 2012 stood at $200000.0 (changed 0.0% YoY), while the FY2011 annual figure was $200000.0, changed 0.0% from the prior year.
• Current Deferred Revenue for Q2 2012 stood at $200000.0, roughly flat from $200000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $200000.0 in Q4 2010, with the low at $200000.0 in Q4 2010.
• The 3-year median for Current Deferred Revenue is $200000.0 (2010), against an average of $200000.0.
• Peak annual rise in Current Deferred Revenue reached 0.0% in 2011, while the deepest fall reached 0.0% in 2011.
• Galectin Therapeutics' Current Deferred Revenue stood at $200000.0 in 2010, then changed by 0.0% to $200000.0 in 2011, then changed by 0.0% to $200000.0 in 2012.
• Business Quant data shows GALT's Current Deferred Revenue at $200000.0 in Q2 2012, $200000.0 in Q1 2012, and $200000.0 in Q4 2011.